Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Depth perception: diabetes in India

Using digital, pharma can engage with diabetes patients in India and build a 3D image of their needs

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

NIHR launches online diabetes research showcase

Aims to raise public aware of diabetes and the importance of research

- PMLiVE

Sanofi and T1D Exchange collaborate to understand needs of children living with diabetes

Aims to deliver recommendations for better disease management and patient outcomes

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

Merck & Co stops development of Januvia, atorvastatin combo

Company spokesperson claims decision is for “business reasons”

- PMLiVE

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links